Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
The Hershey Company Third Quarter 2025 Earnings Call - Sales Surprise, Margin Pain: Top‑Line Raised, EPS Still Set to Fall ~36–37%
Hershey surprised with stronger-than-expected top-line momentum in Q3, raising full year net sales guidance to about 3% while reporting organic constant currency growth of 6.2% and a string of success...
- Reported net sales rose 6.5% in Q3 2025, with organic constant currency net sales growth of 6.2%, ahead of expectations.
- Hershey raised its full year net sales outlook to approximately 3%, up from at least 2%, citing Q3 retail takeaway strength and innovation traction.
- Adjusted EPS guidance was tightened to a decline of approximately 36% to 37% for 2025, the upper half of prior guidance, driven by higher supply chain costs, unfavorable mix, and strategic brand investments.
- +12 more takeaways
Kimberly-Clark Third Quarter 2025 Earnings Call - Transformation Powers Volume-Plus-Mix Growth and 6.5% Productivity
Kimberly-Clark says its Powering Care transformation is gaining momentum: Q3 showed continued volume-plus-mix growth aided by heavy innovation and marketing, while supply-chain changes delivered 6.5% ...
- Powering Care transformation is central to the story, driving innovation-led, volume-plus-mix growth across Kimberly-Clark’s portfolio.
- Q3 gross productivity was 6.5% of adjusted cost of goods sold, the strongest quarter of the year, and management expects full-year gross productivity toward the high end of the 5%–6% range.
- Organic net sales were up 2.5% in Q3, with volume up 2.4%; North America volume-plus-mix was +2.1% in Q3 and International Personal Care (IPC) was +3.6%.
- +16 more takeaways
Utz Brands Q3 2025 Earnings Call - Insignia DSD acquisition primes California expansion
The quarter was a growth quarter with a clear strategic pivot west. Organic net sales rose 3.4%, branded salty snacks grew 5.8%, and management closed on the Insignia DSD deal to jumpstart a Californi...
- Closed acquisition of Insignia International direct store delivery assets to accelerate westward expansion and provide established DSD routes in California and stronger Midwest distribution infrastructure.
- California is a big white space opportunity: $4.1 billion retail salty snack market where Utz currently has roughly 1.9% share, well below its expansion-market average of about 3% and far below Florida at 4.3%.
- Net sales grew 3.4% in Q3 2025, with branded salty snacks organic net sales up 5.8%; this was the seventh consecutive quarter of branded salty snacks growth.
- +16 more takeaways
Haleon Q3 2025 Earnings Call - On track to meet guidance as innovation and supply-chain savings offset US consumption weakness
Haleon reported a steady Q3 with 3.4% organic revenue growth, roughly split between price (1.8%) and volume mix (1.6%), and reiterated full-year guidance of about 3.5% organic growth assuming a normal...
- Organic revenue grew 3.4% in Q3, split between price +1.8% and volume mix +1.6%.
- Reported revenue rose only 0.7%, held back by divestments (-2.3%) and FX (-0.4%); this is the final quarter with divestment drag.
- Oral health led categories, up 6.9%, driven by Sensodyne penetration, clinical platform innovations and ProNamel launches.
- +12 more takeaways
BBVA Q3 2025 Earnings Call - Core revenue momentum and hefty capital buffer let buybacks resume
BBVA reported another strong quarter: core revenues powered by net interest income and fees kept accelerating despite a lower rate backdrop, lending grew briskly across core markets, and profitability...
- Tangible book value per share plus dividends increased 17% year on year and 4.5% in the quarter, highlighting strong value creation.
- BBVA delivered another quarter with net attributable profit above €2.5 billion; cumulative profit for first nine months reached almost €8 billion, up 4.7% YoY in current euros.
- Profitability remains industry-leading, with return on tangible equity at 19.7% and ROE of 18.8% for the first nine months of 2025.
- +16 more takeaways
ASE Technology Holding Co. Q3 2025 Earnings Call - LEAP and Test Drive Growth, FX Shaves Margins as CapEx Accelerates into 2026
ASE reported a quarter of clear operational momentum, led by record ATM revenues and fast-growing test services, but foreign exchange strength in Taiwan trimmed what would otherwise have been a sharpe...
- Q3 revenue NT$168.6 billion, up 12% sequentially and 5% year over year, and up 17% YoY on a US dollar basis.
- Fully diluted EPS for Q3 was NT$2.41, basic EPS NT$2.50; excluding PPA basic EPS would be NT$2.68.
- Foreign exchange was the headline drag, NT moved from NT$31.2 to NT$29.7 per US$ in Q3, a 4.6% appreciation that ASE estimates cut margins roughly 1.4 percentage points sequentially at the holding level and 2.1 points at ATM.
- +12 more takeaways
Sixth Street Specialty Lending, Inc. Second Quarter 2025 Earnings Call - Credit Stabilization Boosts Dividend Coverage, NAV Up; Supplemental Dividend Declared
Sixth Street Specialty Lending reported Q2 adjusted net investment income of $0.56 per share and adjusted net income of $0.64 per share, producing annualized ROEs of roughly 13.1% and 15.1% respective...
- Q2 adjusted net investment income was $0.56 per share; adjusted net income was $0.64 per share. Reported NII and net income inclusive of accrued capital gains fees were $0.54 and $0.63 per share respectively.
- Annualized returns on equity for Q2 were ~13.1% (adjusted NII basis) and ~15.1% (adjusted net income basis); management expects full-year adjusted NII ROE in the top half of the 11.5%–12.5% guidance range, with upside if activity fees remain high.
- NAV rose to $17.17 per share as of 6/30/2025, and adjusted for the supplemental dividend the post-declaration NAV is $17.12 per share. Board approved base dividend $0.46 and a supplemental dividend $0.05 tied to Q2 results.
- +12 more takeaways
Arcutis Biotherapeutics Q3 2025 Earnings Call - Cash flow breakeven accelerated to Q4 2025 on ZORYVE momentum
Arcutis reported a powerful Q3 2025 driven by ZORYVE, with net product revenue of $99.2 million, 22% sequential growth and 122% year-over-year. Management said stronger-than-expected demand, reduced c...
- Net product revenue in Q3 2025 was $99.2 million, up 122% year-over-year and 22% sequentially.
- Total ZORYVE prescriptions rose 13% versus Q2 2025 and 92% versus Q3 2024, with a rolling four-week average exceeding 17,000 weekly scripts.
- ZORYVE Foam 0.3% launch for scalp and body plaque psoriasis (launched June) drove more than 25% quarter-over-quarter growth for the foam SKU and materially contributed to the sales inflection.
- +17 more takeaways
Forestar Q4 FY2025 Earnings Call - Strong liquidity and disciplined land investments amid affordability headwinds
Forestar closed FY2025 with revenue of $1.7 billion, up 10% year over year, and Q4 revenue of $670.5 million. The company highlighted an 11% increase in book value per share to $34.78, nearly $1 billi...
- Q4 revenue was $670.5 million; FY2025 revenue was $1.7 billion, up 10% year over year.
- Q4 net income: $87.0 million, or $1.70 per diluted share; FY net income: $167.9 million, or $3.29 per diluted share.
- Book value per share rose 11% year over year to $34.78, and stockholders' equity ended at approximately $1.8 billion.
- +13 more takeaways
MSCI Third Quarter 2025 Earnings Call - Index and AI‑fuelled product momentum lifts growth, board OKs $3B buyback
MSCI reported a solid Q3 2025: organic revenue +9%, adjusted EBITDA +10%, adjusted EPS +15%+, and run rate growth north of 10%. The company leaned into its index franchise and AI-powered product launc...
- Q3 financials: organic revenue +9%, adjusted EBITDA +10%, adjusted EPS up more than 15% year over year.
- Share buybacks accelerated: $1.25 billion repurchased since the start of Q3, $1.5 billion year-to-date, and board authorized an additional $3 billion.
- Index franchise remains the engine: AUM linked to MSCI indexes reached $6.4 trillion globally, including $2.2 trillion in ETFs and $4.2 trillion in non-ETF products.
- +11 more takeaways